Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00184626

Enrollment

Registered

2005-09-16

Start date

2004-09-10

Completion date

2005-10-24

Last updated

2017-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.

Interventions

DRUGbiphasic insulin aspart

DRUGinsulin glargine

DRUGmetformin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Body mass index equal to or lesser than 35.0 kg/m2 * Currently treated with oral hypoglycaemic drug

Exclusion criteria

* Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator * Any condition that the Investigator and/or the Sponsor feel would interfere with trial participation or evaluation of results

Design outcomes

Primary

Measure	Time frame
HbA1c	Measured at end of treatment (26 weeks)

Secondary

Measure	Time frame
safety variables	—
other glycemic variables	—
Fasting plasma glucose value	—

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026